# Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

> **NCT03061812** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 444 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Rovalpituzumab tesirine
- **DRUG:** Topotecan
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03061812
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-11
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061812, "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03061812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*